Payam Aghassi, MD
Pulmonary Disease · Leominster, MANPI 1093704298
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $80,784 of the $95,584 with a category attached, or 84.5%. 43 manufacturers reported payments, led by AstraZeneca at 45.4% of the total. Reporting peaked in 2021 at $39,656 and has fallen 93.6% since, to $2,536 in 2025. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 653 payments — averaging $146.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$43K
- GSK$37K
- Regeneron Healthcare Solutions, Inc.$9K
- Boehringer Ingelheim$812
- Pulmonx Corporation$656
- Actelion Pharmaceuticals US, Inc.$515
- plus $4K from 37 others
What the payments were for
- Speaking & faculty fees$80,78485%
- Travel & lodging$1,5322%
- Food & beverage$13,10514%
- Education$1630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$39,108
- TRELEGY ELLIPTA$24,017
- DUPIXENT$8,307
- Pulmonx Endobronchial Valve EBV$656
- SMARTVEST$145
- Inspire Upper Airway Stimulation System$120
How this compares
$95,584 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 544 | $474,777 |
| OfevNintedanib Esylate | 25 | $313,728 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 315 | $224,334 |
| Ambrisentan | 12 | $91,959 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 164 | $84,276 |
| Pirfenidone | 13 | $69,778 |
| Breo ElliptaFluticasone/Vilanterol | 102 | $44,978 |
| Arnuity ElliptaFluticasone Furoate | 131 | $39,570 |
| Spiriva RespimatTiotropium Bromide | 38 | $27,975 |
| EliquisApixaban | 29 | $27,158 |
| Wixela InhubFluticasone Propion/Salmeterol | 133 | $18,628 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $17,915 |
| Incruse ElliptaUmeclidinium Bromide | 44 | $17,777 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 539 | $16,228 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 50 | $15,400 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $37,130 | $661,378985 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $812 | $359,61893 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $43,389 | $232,268348 claims |
| PfizerEliquis | $139 | $27,15829 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $69 | $3,50111 claims |
| MerckDulera | $47 | $3,48413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Leominster
- Yaron GoldmanWorcester$843K
- Sarah GrantBrookline$678K
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Fernando MartinezWorcester$375K
- Ana CojocaruFall River$364K
- Adnan MajidBoston$351K
- Adam SmithBurlington$296K
- Nicholas HillBoston$293K
- Elliot IsraelBrookline$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.